Breaking News Instant updates and real-time market news.

ZYNE

Zynerba

$18.20

-0.18 (-0.98%)

, GWPH

GW Pharmaceuticals

$94.99

0.85 (0.90%)

07:58
06/12/17
06/12
07:58
06/12/17
07:58

Zynerba an 'excellent value' compared to GW Pharmaceuticals, says Maxim

Maxim analyst Gabrielle Zhou said she views Zynerba's (ZYNE) product candidates as "de-risked" alternatives to GW Pharmaceuticals' (GWPH) and calls the stock an "excellent value play" compared to GW, citing the facts that ZYN002 has a better safety and bioavailability profile than GW Pharma's Epidiolex. ZYN002 is also synthetic, not plant based, which could lead to higher margins and better quality control, Zhou tells investors. She keeps a Buy rating and $32 price target on Zynerba shares, adding that 2017 could be "transformational" for the company.

ZYNE

Zynerba

$18.20

-0.18 (-0.98%)

GWPH

GW Pharmaceuticals

$94.99

0.85 (0.90%)

  • 13

    Jun

ZYNE Zynerba
$18.20

-0.18 (-0.98%)

02/24/17
MAXM
02/24/17
INITIATION
Target $32
MAXM
Buy
Zynerba initiated with a Buy at Maxim
Maxim analyst Lauren Chung started Zynerba with a Buy rating and $32 price target, stating that 2017 could be a transformational year as cannabis-based therapies are starting to gain acceptance in the medical community and the company's three ongoing phase II trials for its lead cannabis-based candidate are expected to report data in epilepsy, osteoarthritis, and Fragile X syndrome.
03/20/17
ROTH
03/20/17
NO CHANGE
Target $30
ROTH
Buy
Zynerba price target raised to $30 from $25 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Zynerba to $30 from $25, citing his increasing confidence in the outcome of STAR 1. The analyst reiterates a Buy rating on the shares.
03/28/17
HCWC
03/28/17
NO CHANGE
Target $30
HCWC
Buy
Zynerba price target raised to $30 from $22 at H.C. Wainwright
H.C. Wainwright analyst Corey Davis raised his price target for Zynerba Pharmaceuticals to $30 after the company specified yesterday that both its Phase 2 studies with ZYN002, in epilepsy and osteoarthritis pain, will read out in July or August, with epilepsy coming first. The analyst thinks the gel has a "high chance of working." Medical marijuana has utility in a number of different settings and regulators would prefer to have the active compound isolated, regulated, and delivered in a consistent manner, Davis tells investors in a research note. The analyst keeps a Buy rating on Zynerba following the company's Q4 results.
03/31/17
OPCO
03/31/17
NO CHANGE
Target $29
OPCO
Outperform
Oppenheimer remains positive on Zynerba ahead of near-term catalysts
Oppenheimer analyst Derek Archila notes that Zynerba reported Q4 financial results and provided updates on its three ongoing Phase 2 studies for ZYN002 in adult epilepsy, knee osteoarthritis, and Fragile X syndrome, and remains on track to report data for its Phase 2 trials in adult epilepsy and knee osteoarthritis in July/August. Ahead of these near-term catalysts, the analyst remains positive on the shares, though he reminds investors Zynerba is a high-risk/high-reward potential investment. Archila reiterates an Outperform rating and $29 price target on the shares.
GWPH GW Pharmaceuticals
$94.99

0.85 (0.90%)

03/02/17
JANY
03/02/17
NO CHANGE
Target $55
JANY
Sell
GW Pharmaceuticals expectations, valuation remain too high, says Janney Capital
Janney Capital analyst Ken Trbovich raised his estimates for GW Pharmaceuticals and increased his fair value estimate for the shares to $55, citing the "excitement" he heard among physicians who regularly treat patients with Epidiolex during the Annual Epilepsy Society meeting last December. However, he continues to think regulatory and commercial challenges will likely prevent Epidiolex from achieving high expectations set by the market, even if the drug is approved on first review for Dravet Syndrome and LGS and the subsequent studies in infantile spasm and tuberous sclerosis succeed. Trbovich, who notes that consensus estimates call for Epidiolex to hit $900M in sales in just 3-4 years even though the most recent FDA-approved drugs for orphan epilepsy indications had sales in the range of $100M-$300M 4-8 years after launch, keeps a Sell rating on GW shares.
04/21/17
MAXM
04/21/17
INITIATION
Target $135
MAXM
Buy
GW Pharmaceuticals initiated with a Buy at Maxim
Maxim analyst Lauren Chung initiated GW Pharmaceuticals with a Buy rating and $135 price target, calling the company the "market leader" in cannabis therapeutics with a first-mover advantage in epilepsy.
05/25/17
LEER
05/25/17
NO CHANGE
LEER
Outperform
NEJM validation for Epidiolex, but controversy remains, says Leerink
Leerink analyst Paul Matteis believes publication of the first Dravet study in the New England Journal of Medicine offers "further validation of the robustness" of the positive phase III trial for GW Pharmaceuticals' Epidiolex. No new safety issues were disclosed and statistical sensitivity analyses corroborated the positive primary efficacy analysis, Matteis tells investors in a research note. Not included in the publication, however, is further color on the clobazam drug-drug interaction, which continues to remain a subject of investor controversy and interest heading into the mid-2017 new drug application filing, Matteis writes. He reiterates an Outperform rating on GW shares.
06/09/17
MAXM
06/09/17
NO CHANGE
MAXM
Buy
GW Pharmaceuticals orphan designation an incremental positive, says Maxim
Maxim analyst Gabrielle Zhou noted that GW Pharmaceuticals received FDA orphan designation for cannabidivarin for treatment of Fragile X syndrome, calling the news an incremental positive. The analyst, who notes that the next investor focus is the phase 2 data expected to be announced mid-2017 for GWP42006 in adult epilepsy, keeps a Buy rating on GW shares.

TODAY'S FREE FLY STORIES

02:45
11/21/17
11/21
02:45
11/21/17
02:45
General news
FX Update: Narrow ranges have been prevailing »

FX Update: Narrow ranges…

SPN

Superior Energy

$8.81

-0.14 (-1.56%)

21:18
11/20/17
11/20
21:18
11/20/17
21:18
Upgrade
Superior Energy rating change at SunTrust »

Superior Energy upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$78.90

-0.59 (-0.74%)

, LOW

Lowe's

$81.46

1.24 (1.55%)

20:25
11/20/17
11/20
20:25
11/20/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MDT

Medtronic

$78.90

-0.59 (-0.74%)

LOW

Lowe's

$81.46

1.24 (1.55%)

ADI

Analog Devices

$93.07

2.65 (2.93%)

DLTR

Dollar Tree

$97.11

2.5 (2.64%)

HRL

Hormel Foods

$33.40

0.28 (0.85%)

CPB

Campbell Soup

$49.93

0.21 (0.42%)

BURL

Burlington Stores

$106.55

1.82 (1.74%)

SIG

Signet Jewelers

$75.84

-0.74 (-0.97%)

DSW

DSW

$22.53

0.38 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 27

    Nov

  • 01

    Dec

  • 07

    Dec

  • 08

    Dec

  • 09

    Jan

CCLP

CSI Compressco

$5.28

-0.16 (-2.94%)

19:32
11/20/17
11/20
19:32
11/20/17
19:32
Hot Stocks
CSI Compressco names Owen Serjeant president »

CSI Compressco announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAT

Applied Materials

$57.62

1.13 (2.00%)

, AAPL

Apple

$169.98

-0.17 (-0.10%)

19:04
11/20/17
11/20
19:04
11/20/17
19:04
Periodicals
Applied Materials expected to purchase former Apple complex, Mercury News says »

An office complex that…

AMAT

Applied Materials

$57.62

1.13 (2.00%)

AAPL

Apple

$169.98

-0.17 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 28

    Nov

  • 29

    Nov

FOX

21st Century Fox

$29.90

-0.58 (-1.90%)

, FOXA

21st Century Fox

$30.66

-0.49 (-1.57%)

18:21
11/20/17
11/20
18:21
11/20/17
18:21
Periodicals
Fox reaches $90M settlement over sexual harassment scandal, Reuters says »

21st Century Fox reached…

FOX

21st Century Fox

$29.90

-0.58 (-1.90%)

FOXA

21st Century Fox

$30.66

-0.49 (-1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$188.00

2.87 (1.55%)

18:19
11/20/17
11/20
18:19
11/20/17
18:19
Hot Stocks
Muddy Waters says Alibaba numbers 'obviously fake' »

Short seller Muddy Waters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PANW

Palo Alto Networks

$142.53

-0.19 (-0.13%)

, CHKP

Check Point

$102.98

0.83 (0.81%)

18:15
11/20/17
11/20
18:15
11/20/17
18:15
Recommendations
Palo Alto Networks, Check Point, Fortinet analyst commentary at JPMorgan »

Palo Alto quarter…

PANW

Palo Alto Networks

$142.53

-0.19 (-0.13%)

CHKP

Check Point

$102.98

0.83 (0.81%)

FTNT

Fortinet

$40.77

0.46 (1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 07

    Dec

  • 11

    Dec

  • 11

    Dec

  • 17

    Jan

  • 17

    Jan

AMZN

Amazon.com

$1,126.31

-3.57 (-0.32%)

18:14
11/20/17
11/20
18:14
11/20/17
18:14
Hot Stocks
Amazon announces cloud software for U.S spy agencies AWS Secret Region »

Amazon announced the new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

BIVV

Bioverativ

$50.76

-5.35 (-9.53%)

, RHHBY

Roche

$30.82

1.72 (5.91%)

18:08
11/20/17
11/20
18:08
11/20/17
18:08
Recommendations
Deutsche cuts Bioverativ target to $53 after positive Roche data »

Deutsche Bank analyst…

BIVV

Bioverativ

$50.76

-5.35 (-9.53%)

RHHBY

Roche

$30.82

1.72 (5.91%)

SHPG

Shire

$141.37

-6 (-4.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

  • 09

    Dec

  • 23

    Dec

  • 23

    Feb

CUBI

Customers Bancorp

$27.04

0.28 (1.05%)

18:04
11/20/17
11/20
18:04
11/20/17
18:04
Hot Stocks
Customers Bancorp: Flagship could raise capital in IPO transaction in 1H18 »

Customers Bancorp, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

18:04
11/20/17
11/20
18:04
11/20/17
18:04
Hot Stocks
AT&T CEO says has offered DOJ solutions that were not accepted »

Says DOJ suit throws lots…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

NGD

New Gold

$3.21

-0.02 (-0.62%)

18:02
11/20/17
11/20
18:02
11/20/17
18:02
Hot Stocks
New Gold announces sale of Peak Mines for $58M »

New Gold announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMI

Intermolecular

$1.31

0.1 (8.26%)

18:01
11/20/17
11/20
18:01
11/20/17
18:01
Hot Stocks
Intermolecular partners with SITRI to develop MtM technologies »

Intermolecular, Inc and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 28

    Nov

  • 29

    Nov

CMCSA

Comcast

$35.83

-0.33 (-0.91%)

18:00
11/20/17
11/20
18:00
11/20/17
18:00
Initiation
Comcast initiated at Buckingham »

Comcast initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNX

Mellanox

$51.05

1 (2.00%)

17:59
11/20/17
11/20
17:59
11/20/17
17:59
Hot Stocks
Mellanox up nearly 6% after Starboard discloses a 9.8% stake in the company »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 05

    Dec

  • 06

    Dec

PLNT

Planet Fitness

$30.15

0.07 (0.23%)

17:58
11/20/17
11/20
17:58
11/20/17
17:58
Initiation
Planet Fitness initiated at DA Davidson »

Planet Fitness initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TER

Teradyne

$44.43

0.86 (1.97%)

17:57
11/20/17
11/20
17:57
11/20/17
17:57
Downgrade
Teradyne rating change at Deutsche Bank »

Teradyne downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 28

    Nov

  • 29

    Nov

CBS

CBS

$55.93

-0.81 (-1.43%)

17:56
11/20/17
11/20
17:56
11/20/17
17:56
Periodicals
CBS News suspends Charlie Rose following sexual harassment claims, AP says 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBS

CBS

$55.93

-0.81 (-1.43%)

17:55
11/20/17
11/20
17:55
11/20/17
17:55
Periodicals
Eight women accuse Charlie Rose of sexual harassment, Washington Post says »

Eight women have said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLNX

Mellanox

$51.05

1 (2.00%)

, MRVL

Marvell

$21.59

1.3 (6.41%)

17:53
11/20/17
11/20
17:53
11/20/17
17:53
Hot Stocks
Starboard Value reports 9.8% stake in Mellanox, may seek talks »

Peter A. Feld, a…

MLNX

Mellanox

$51.05

1 (2.00%)

MRVL

Marvell

$21.59

1.3 (6.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 28

    Nov

  • 05

    Dec

  • 06

    Dec

CDXS

Codexis

17:46
11/20/17
11/20
17:46
11/20/17
17:46
Hot Stocks
Breaking Hot Stocks news story on Codexis »

Telemark Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

17:45
11/20/17
11/20
17:45
11/20/17
17:45
Hot Stocks
AT&T CEO says giving up control of CNN is a 'non-starter' »

Says plenty of solutions…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

BBY

Best Buy

$56.35

0.52 (0.93%)

17:45
11/20/17
11/20
17:45
11/20/17
17:45
Conference/Events
Best Buy management to meet with SunTrust »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

17:43
11/20/17
11/20
17:43
11/20/17
17:43
Hot Stocks
AT&T CEO says DOJ suit 'defies logic' »

Says has offered…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.